Literature DB >> 23054090

Aggregation mechanism of an IgG2 and two IgG1 monoclonal antibodies at low pH: from oligomers to larger aggregates.

Paolo Arosio1, Simonetta Rima, Massimo Morbidelli.   

Abstract

PURPOSE: To identify the aggregation mechanism and the stability characteristics of three different monoclonal antibodies under acidic conditions.
METHODS: The aggregation kinetics is analyzed by a combination of light scattering, size exclusion chromatography and fluorescence techniques and the aggregation data are correlated to protein structure, hydrophobicity, charge and antibody subclass.
RESULTS: In the investigated conditions, the antibody aggregation follows a mechanism consisting of two-steps: reversible monomer oligomerization followed by irreversible cluster-cluster aggregation. The kinetics of the two steps is differently affected by the operating conditions: mild destabilizing conditions induce formation of oligomers which are stable within weeks, while stronger denaturing conditions promote aggregation of oligomers to larger aggregates which eventually precipitate. For different antibodies significant differences in both oligomerization and growth rates are found, even for antibodies belonging to the same subclass. For all antibodies the aggregate formation is accompanied by a structure re-organization with an increase in the ordered β-sheet structures. At low pH the aggregation propensity of the investigated antibodies does not correlate with antibody subclass, surface net charge and hydrophobicity of the non-native state.
CONCLUSIONS: The aggregation mechanism of three antibodies in acidic conditions as well as differences and analogies in their stability behavior has been characterized.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23054090     DOI: 10.1007/s11095-012-0885-3

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  41 in total

1.  Classification of protein aggregates.

Authors:  Linda O Narhi; Jeremy Schmit; Karoline Bechtold-Peters; Deepak Sharma
Journal:  J Pharm Sci       Date:  2011-10-11       Impact factor: 3.534

2.  Nonnative aggregation of an IgG1 antibody in acidic conditions, part 2: nucleation and growth kinetics with competing growth mechanisms.

Authors:  Rebecca K Brummitt; Douglas P Nesta; Liuquan Chang; Andrew M Kroetsch; Christopher J Roberts
Journal:  J Pharm Sci       Date:  2011-01-06       Impact factor: 3.534

3.  Glycosylation influences on the aggregation propensity of therapeutic monoclonal antibodies.

Authors:  Veysel Kayser; Naresh Chennamsetty; Vladimir Voynov; Kurt Forrer; Bernhard Helk; Bernhardt L Trout
Journal:  Biotechnol J       Date:  2011-01       Impact factor: 4.677

4.  Engineering aggregation resistance in IgG by two independent mechanisms: lessons from comparison of Pichia pastoris and mammalian cell expression.

Authors:  Jonas V Schaefer; Andreas Plückthun
Journal:  J Mol Biol       Date:  2012-01-27       Impact factor: 5.469

5.  Elucidation of two major aggregation pathways in an IgG2 antibody.

Authors:  Nicholas Van Buren; Douglas Rehder; Himanshu Gadgil; Masazumi Matsumura; Jaby Jacob
Journal:  J Pharm Sci       Date:  2009-09       Impact factor: 3.534

6.  IgG particle formation during filling pump operation: a case study of heterogeneous nucleation on stainless steel nanoparticles.

Authors:  Anil K Tyagi; Theodore W Randolph; Aichun Dong; Kevin M Maloney; Carl Hitscherich; John F Carpenter
Journal:  J Pharm Sci       Date:  2009-01       Impact factor: 3.534

7.  Potential inaccurate quantitation and sizing of protein aggregates by size exclusion chromatography: essential need to use orthogonal methods to assure the quality of therapeutic protein products.

Authors:  John F Carpenter; Theodore W Randolph; Wim Jiskoot; Daan J A Crommelin; C Russell Middaugh; Gerhard Winter
Journal:  J Pharm Sci       Date:  2010-05       Impact factor: 3.534

Review 8.  The critical role of mobile phase composition in size exclusion chromatography of protein pharmaceuticals.

Authors:  Tsutomu Arakawa; Daisuke Ejima; Tiansheng Li; John S Philo
Journal:  J Pharm Sci       Date:  2010-04       Impact factor: 3.534

9.  Aggregation stability of a monoclonal antibody during downstream processing.

Authors:  Paolo Arosio; Giuliano Barolo; Thomas Müller-Späth; Hua Wu; Massimo Morbidelli
Journal:  Pharm Res       Date:  2011-03-30       Impact factor: 4.200

10.  Inhibition of agitation-induced aggregation of an IgG-antibody by hydroxypropyl-beta-cyclodextrin.

Authors:  Tim Serno; John F Carpenter; Theodore W Randolph; Gerhard Winter
Journal:  J Pharm Sci       Date:  2010-03       Impact factor: 3.534

View more
  26 in total

1.  Monoclonal Antibodies Follow Distinct Aggregation Pathways During Production-Relevant Acidic Incubation and Neutralization.

Authors:  Thomas Skamris; Xinsheng Tian; Matthias Thorolfsson; Hanne Sophie Karkov; Hanne B Rasmussen; Annette E Langkilde; Bente Vestergaard
Journal:  Pharm Res       Date:  2015-11-12       Impact factor: 4.200

Review 2.  High-throughput biophysical analysis of protein therapeutics to examine interrelationships between aggregate formation and conformational stability.

Authors:  Rajoshi Chaudhuri; Yuan Cheng; C Russell Middaugh; David B Volkin
Journal:  AAPS J       Date:  2013-10-31       Impact factor: 4.009

3.  Characterizing Thermal Transitions of IgG with Mass Spectrometry.

Authors:  Christopher J Brown; Daniel W Woodall; Tarick J El-Baba; David E Clemmer
Journal:  J Am Soc Mass Spectrom       Date:  2019-07-30       Impact factor: 3.109

4.  Structural characterization of IgG1 mAb aggregates and particles generated under various stress conditions.

Authors:  Srivalli N Telikepalli; Ozan S Kumru; Cavan Kalonia; Reza Esfandiary; Sangeeta B Joshi; C Russell Middaugh; David B Volkin
Journal:  J Pharm Sci       Date:  2014-01-22       Impact factor: 3.534

5.  Radar chart array analysis to visualize effects of formulation variables on IgG1 particle formation as measured by multiple analytical techniques.

Authors:  Cavan Kalonia; Ozan S Kumru; Jae Hyun Kim; C Russell Middaugh; David B Volkin
Journal:  J Pharm Sci       Date:  2013-10-09       Impact factor: 3.534

6.  Protein aggregation and mitigation strategy in low pH viral inactivation for monoclonal antibody purification.

Authors:  Weixin Jin; Zizhuo Xing; Yuanli Song; Chao Huang; Xuankuo Xu; Sanchayita Ghose; Zheng Jian Li
Journal:  MAbs       Date:  2019-09-02       Impact factor: 5.857

Review 7.  Structure, heterogeneity and developability assessment of therapeutic antibodies.

Authors:  Yingda Xu; Dongdong Wang; Bruce Mason; Tony Rossomando; Ning Li; Dingjiang Liu; Jason K Cheung; Wei Xu; Smita Raghava; Amit Katiyar; Christine Nowak; Tao Xiang; Diane D Dong; Joanne Sun; Alain Beck; Hongcheng Liu
Journal:  MAbs       Date:  2018-12-17       Impact factor: 5.857

8.  Explaining the non-newtonian character of aggregating monoclonal antibody solutions using small-angle neutron scattering.

Authors:  Maria Monica Castellanos; Jai A Pathak; William Leach; Steven M Bishop; Ralph H Colby
Journal:  Biophys J       Date:  2014-07-15       Impact factor: 4.033

9.  Acid-induced aggregation propensity of nivolumab is dependent on the Fc.

Authors:  Boning Liu; Huaizu Guo; Jin Xu; Ting Qin; Lu Xu; Junjie Zhang; Qingcheng Guo; Dapeng Zhang; Weizhu Qian; Bohua Li; Jianxin Dai; Sheng Hou; Yajun Guo; Hao Wang
Journal:  MAbs       Date:  2016-06-16       Impact factor: 5.857

Review 10.  Analytical comparability study of recombinant monoclonal antibody therapeutics.

Authors:  Alexandre Ambrogelly; Stephen Gozo; Amit Katiyar; Shara Dellatore; Yune Kune; Ram Bhat; Joanne Sun; Ning Li; Dongdong Wang; Christine Nowak; Alyssa Neill; Gomathinayagam Ponniah; Cory King; Bruce Mason; Alain Beck; Hongcheng Liu
Journal:  MAbs       Date:  2018-03-20       Impact factor: 5.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.